During the recent session, Virax Biolabs Group Ltd (NASDAQ:VRAX)’s traded shares were 1.43 million, with the beta value of the company hitting 1.52. At the last check today, the stock’s price was $4.78, reflecting an intraday loss of -1.85% or -$0.09. The 52-week high for the VRAX share is $9.00, that puts it down -88.28 from that peak though still a striking 87.45% gain since the share price plummeted to a 52-week low of $0.60. The company’s market capitalization is $11.28M, and the average intraday trading volume over the past 10 days was 24.7 million shares, and the average trade volume was 5.39 million shares over the past three months.
Virax Biolabs Group Ltd (NASDAQ:VRAX) trade information
Virax Biolabs Group Ltd (VRAX) registered a -1.85% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.85% in intraday trading to $4.78, hitting a weekly high. The stock’s 5-day price performance is -7.72%, and it has moved by 283.94% in 30 days. Based on these gigs, the overall price performance for the year is 29.15%. The short interest in Virax Biolabs Group Ltd (NASDAQ:VRAX) is 0.26 million shares and it means that shorts have 0.68 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -52.25%.
VRAX Dividends
Virax Biolabs Group Ltd is due to release its next quarterly earnings in September. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Virax Biolabs Group Ltd (NASDAQ:VRAX)’s Major holders
Data provided on Jun 30, 2024 indicates that Fidelity NASDAQ Composite Index Fund owns about 542.0 shares. This amounts to just over 0.02 percent of the company’s overall shares, with a $2601.0 market value.
